BioCentury
ARTICLE | Clinical News

Subcutaneous semaglutide: Additional Phase IIIa data

September 19, 2016 7:00 AM UTC

Additional data from the double-blind, international Phase IIIa SUSTAIN 5 trial in 397 Type II diabetics showed that once-weekly 0.5 and 1 mg subcutaneous semaglutide as an add-on to basal insulin alo...